(Z)-9-nonadecene

CAS No. 51865-02-2

(Z)-9-nonadecene( 9-Nonadecene )

Catalog No. M29430 CAS No. 51865-02-2

(Z)-9-Nonadecene was identified the first time in T. melanocephalum. (Z)-9-Nonadecene is a major component in mandibular glands and iridodials are produced in pygidial glands.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 302 Get Quote
10MG 447 Get Quote
25MG 808 Get Quote
50MG 1226 Get Quote
100MG 1797 Get Quote
200MG 2695 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (Z)-9-nonadecene
  • Note
    Research use only, not for human use.
  • Brief Description
    (Z)-9-Nonadecene was identified the first time in T. melanocephalum. (Z)-9-Nonadecene is a major component in mandibular glands and iridodials are produced in pygidial glands.
  • Description
    (Z)-9-Nonadecene was identified the first time in T. melanocephalum. (Z)-9-Nonadecene is a major component in mandibular glands and iridodials are produced in pygidial glands.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    9-Nonadecene
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    51865-02-2
  • Formula Weight
    530.99
  • Molecular Formula
    C38H74
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCCCCCCCC/C=C\CCCCCCCCCCCCCCCCC/C=C\CCCCCCCC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Gastric Inhibitory P...

    Gastric Inhibitory Polypeptide (6-30) amide (human) is an incretin hormone. Gastric Inhibitory Polypeptide (6-30) amide (human) can be used for the research of diabete.

  • Kitasamycin

    Kitasamycin?(INN) is a macrolide antibiotic. It is produced by?Streptomyces kitasatoensis.

  • JNJ-26990990

    JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate.